Literature DB >> 10942246

Mantle cell lymphoma proliferates upon IL-10 in the CD40 system.

H P Visser1, M Tewis, R Willemze, J C Kluin-Nelemans.   

Abstract

Mantle cell lymphoma (MCL) is a B cell non-Hodgkin's lymphoma, characterized by a poor response to therapy and short survival. To assess the proliferative capacity, we cultured MCL cells, using irradiated 3T6 mouse fibroblasts transfected with human CD40L ('CD40 system') in the presence of different cytokines. Proliferation was measured by 3H-thymidine incorporation and by CFSE fluorescence. Thirteen out of 16 MCL cases proliferated well in the CD40 system. In 10 cases a strong response upon further addition of IL-10 was seen, whereas IL-4 had an additional effect in only four cases. CFSE staining of cells before and after culture showed an increased number of cell divisions in the IL-10/CD40L stimulated cells. The MCL cells remained CD5+CD19+. Neither plasma cell differentiation nor isotype switching was seen. The light chain expression was strictly monoclonal. IL-1beta, IL-2, IL-6, G-CSF and GM-CSF did not stimulate MCL proliferation. IL-10 receptor expression correlated with the response to IL-10 in the culture system and the effect of added IL-10 could be blocked by antibodies directed against IL-10 and the IL-10 receptor. Autocrine IL-10 production by the MCL cells was detected in eight of 10 cases tested. IL-10 receptor blocking decreased proliferation when no exogenous IL-10 was used in four of seven cases tested. EBV assessed by EBER in situ hybridization was not detected in six cases tested. In conclusion, MCL can successfully be cultured upon CD40 stimulation if 3T6 CD40L+ cells are used. In this context IL-10 is a costimulatory factor. IL-10 receptor expression seems to correlate with response to CD40 crosslinking and IL-10. Autocrine IL-10 production might play a role in the proliferation of this lymphoma. This culture system may be useful to test new treatment strategies for this, thus far, therapy-resistant lymphoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942246     DOI: 10.1038/sj.leu.2401829

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  15 in total

1.  Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion.

Authors:  Paul M Barr; Chungwen Wei; James Roger; Julia Schaefer-Cutillo; Jennifer L Kelly; Alexander F Rosenberg; John Jung; Iñaki Sanz; Jonathan W Friedberg
Journal:  Clin Immunol       Date:  2012-01-05       Impact factor: 3.969

Review 2.  Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications.

Authors:  Daisuke Ito; Aric M Frantz; Jaime F Modiano
Journal:  Vet Immunol Immunopathol       Date:  2014-02-24       Impact factor: 2.046

Review 3.  Molecular pathogenesis of mantle cell lymphoma.

Authors:  Pedro Jares; Dolors Colomer; Elias Campo
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

4.  CD40·FasL and CTLA-4·FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling.

Authors:  Ariel Orbach; Jacob Rachmilewitz; Noam Shani; Yonatan Isenberg; Miriam Parnas; Jui-Han Huang; Mark L Tykocinski; Michal Dranitzki-Elhalel
Journal:  Am J Pathol       Date:  2010-11-18       Impact factor: 4.307

5.  CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies.

Authors:  Daisuke Ito; Aric M Frantz; Christina Williams; Rachael Thomas; Robert C Burnett; Anne C Avery; Matthew Breen; Nicola J Mason; Timothy D O'Brien; Jaime F Modiano
Journal:  Leuk Lymphoma       Date:  2012-02-03

6.  Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.

Authors:  Fanny Baran-Marszak; Mohand Boukhiar; Stéphanie Harel; Christelle Laguillier; Claudine Roger; Remy Gressin; Antoine Martin; Remi Fagard; Nadine Varin-Blank; Florence Ajchenbaum-Cymbalista; Dominique Ledoux
Journal:  Haematologica       Date:  2010-07-27       Impact factor: 9.941

7.  Early Generated B-1-Derived B Cells Have the Capacity To Progress To Become Mantle Cell Lymphoma-like Neoplasia in Aged Mice.

Authors:  Kyoko Hayakawa; Anthony M Formica; Yuka Nakao; Daiju Ichikawa; Susan A Shinton; Joni Brill-Dashoff; Mitchell R Smith; Herbert C Morse; Richard R Hardy
Journal:  J Immunol       Date:  2018-06-13       Impact factor: 5.422

8.  Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells.

Authors:  Norihiko Kawamata; John Chen; H Phillip Koeffler
Journal:  Blood       Date:  2007-07-02       Impact factor: 22.113

9.  Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Authors:  Betty Y Chang; Michelle Francesco; Martin F M De Rooij; Padmaja Magadala; Susanne M Steggerda; Min Mei Huang; Annemieke Kuil; Sarah E M Herman; Stella Chang; Steven T Pals; Wyndham Wilson; Adrian Wiestner; Marcel Spaargaren; Joseph J Buggy; Laurence Elias
Journal:  Blood       Date:  2013-08-12       Impact factor: 22.113

10.  Cancer Tissue Engineering: A Novel 3D Polystyrene Scaffold for In Vitro Isolation and Amplification of Lymphoma Cancer Cells from Heterogeneous Cell Mixtures.

Authors:  Carlos E Caicedo-Carvajal; Qing Liu; Yvonne Remache; Andre Goy; K Stephen Suh
Journal:  J Tissue Eng       Date:  2011-09-05       Impact factor: 7.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.